title: New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
abstract: Antitumor necrosis factor α agents have dramatically changed the management of inflammatory bowel disease (IBD). However, a significant proportion of patients does not respond or lose response over time. Hence, there is an urgent need for new molecules, with different mechanisms of action, and with a targeted and more effective approach. These new drugs include either small molecules or biological agents. We describe the three most promising classes of molecules in the field of IBD: anti-adhesion, anti-interleukin 12/23 and anti-Janus Kinases therapies.
authors.affiliation: Department of Gastroenterology, Endoscopy Unit, Humanitas Research Hospital , Rozzano, Milan , Italy.
authors.forename: Ivana
authors.initials: I
authors.lastname: Bravatà
authors.forename: Gionata
authors.initials: G
authors.lastname: Fiorino
authors.forename: Mariangela
authors.initials: M
authors.lastname: Allocca
authors.forename: Alessandro
authors.initials: A
authors.lastname: Repici
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology; D018664:Interleukin-12 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors; D053612:Janus Kinases / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D007166:Immunosuppressive Agents; D053759:Interleukin-23; D018664:Interleukin-12; D053612:Janus Kinases
keywords: Crohn’s disease; adhesion molecules; anti-Janus kinases; anti-integrins; anti-interleukin 12/23; inflammatory bowel disease; ulcerative colitis